Ray A Olsson
Overview
Explore the profile of Ray A Olsson including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
18
Citations
183
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Holschbach M, Bier D, Wutz W, Willbold S, Olsson R
Org Lett
. 2009 Sep;
11(19):4266-9.
PMID: 19725521
In human blood, the PET radiotracer [(18)F]CPFPX (1) is metabolized to numerous metabolites, one (M1) being the most prominent in plasma 30 min p.i. Because the mass of injected tracer...
2.
Sihver W, Schulze A, Wutz W, Stusgen S, Olsson R, Bier D, et al.
Eur J Pharmacol
. 2009 Jun;
616(1-3):107-14.
PMID: 19545560
The adenosine A(2A) receptor in the basal ganglia is involved in the control of movement and plays a role in movement disorders such as Parkinsonism. Developing ligands to evaluate that...
3.
Drewes B, Sihver W, Willbold S, Olsson R, Coenen H
Nucl Med Biol
. 2007 Jun;
34(5):531-9.
PMID: 17591553
Positron emission tomography (PET) imaging of dopamine transporter (DAT) density in the brain is a potentially valuable tool for studying the etiopathology of degenerative brain disorders. The present study evaluated...
4.
Bier D, Holschbach M, Wutz W, Olsson R, Coenen H
Drug Metab Dispos
. 2006 Jan;
34(4):570-6.
PMID: 16415116
Studies of plasma from mice, rats, and human volunteers evaluated methods for the extraction and quantification of the positron emission tomography ligand [(18)F]8-cyclopentyl-3-(3-fluoropropyl)-1-propylxanthine ([(18)F]CPFPX) and identification of its metabolites in...
5.
Holschbach M, Bier D, Stusgen S, Wutz W, Sihver W, Coenen H, et al.
Eur J Med Chem
. 2005 Nov;
41(1):7-15.
PMID: 16289482
The brain A2A adenosine receptor (A2AAR) participates with the dopamine D2 receptor in the control of movement and also might influence behavior. Because PET is an important tool for studying...
6.
Chordia M, Zigler M, Murphree L, Figler H, Macdonald T, Olsson R, et al.
J Med Chem
. 2005 Aug;
48(16):5131-9.
PMID: 16078833
Allosteric enhancers (AEs) of the A(1) adenosine receptor (A(1)AR) have potential as drugs for treating neurological, cardiovascular, and renal diseases. This report describes the synthesis and evaluation of a series...
7.
Holschbach M, Bier D, Wutz W, Sihver W, Schuller M, Olsson R
Eur J Med Chem
. 2005 May;
40(5):421-37.
PMID: 15893016
The importance of the brain A2A adenosine receptor (A(2A)AR) in movement disorders urges the development of radiolabeled ligands for imaging those receptors by positron emission tomography (PET). This study evaluated...
8.
18F-CPFPX PET identifies changes in cerebral A1 adenosine receptor density caused by glioma invasion
Bauer A, Langen K, Bidmon H, Holschbach M, Weber S, Olsson R, et al.
J Nucl Med
. 2005 Mar;
46(3):450-4.
PMID: 15750158
Unlabelled: Adenosine plays a critical role in both tumor proliferation and the cerebral response to tumor invasion. We used 8-cyclopentyl-3-(3-18F-fluoropropyl)-1-propylxanthine (18F-CPFPX) PET to investigate A1 adenosine receptor (A1AR) density as...
9.
10.
Meyer P, Bier D, Holschbach M, Boy C, Olsson R, Coenen H, et al.
J Cereb Blood Flow Metab
. 2004 Apr;
24(3):323-33.
PMID: 15091113
Adenosine is an important neuromodulator. Basic cerebral effects of adenosine are exerted by the A1 adenosine receptor (A1AR), which is accessible in vivo by the novel ligand [F]8-cyclopentyl-3-(3-fluoropropyl)-1-propylxanthine ([F]CPFPX) and...